Independent trial affirms potential of Chemeq’s antimicrobial
20 May, 2004 by Graeme O'NeillAn independent trial of the polymeric antimicrobial developed by Perth pharmaceutical company Chemeq (ASX:CMQ) has confirmed the drug’s potential to improve disease control in the poultry industry, while transforming its knife-edge economics.
Regenera to list in early June
19 May, 2004 by Renate KrelleThe CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
Anadis to supply nutraceutical to Chinese military
19 May, 2004 by Graeme O'NeillMelbourne biotech Anadis Limited (ASX:ANX) has announced the first sale to China of its bovine colostrum-based nutraceutical – a 3-tonne consignment destined to be used as a health food by the Chinese military and other agencies, to build immunity to enteric diseases.
New BIF funding up for grabs
17 May, 2004 by Renate KrelleAn undisclosed amount of new funding will be made available under the sixth round of the federal Biotechnology Innovation Fund (BIF), newly rebadged as part of the $1 billion, five-year Commercial Ready program.
Dynamic Hearing licenses software to Germany’s Interton
17 May, 2004 by Melissa TrudingerHearing aid software developer Dynamic Hearing has entered into a licensing agreement with German hearing aid manufacturer Interton Hoergeraete.
Cryptome lures expat home for advisory role
14 May, 2004 by Renate KrelleMelbourne-based proteomics researcher Cryptome Pharmaceuticals has lured Dr Paul Cossum, an Australian who for the last 20 years has worked in American biopharmas, to join the company. As a scientific consultant, Cossum will provide advice on drug development and regulatory affairs.
PanBio to raise $7 million to speed products to market
13 May, 2004 by Melissa TrudingerDiagnostics company Panbio (ASX: PBO) has raised AUD$3 million in a placement to existing and new shareholders at a price of $0.42 per share, and plans to raise a further $4.2 million through a share purchase plan to existing shareholders at the same price.
Monsanto drops Australian GM canola program
12 May, 2004 by Graeme O'NeillMonsanto Australia will make no further investment in efforts to commercialise its genetically modified (GM) herbicide-tolerant Roundup Ready canola in Australia for at least 12 months.
VRI launches probiotics into pharmacies
12 May, 2004 by Renate KrelleVRI BioMedical announced today that its probiotics range for the treatment of irritable bowel syndrome, diarrhoea and general intestinal health, is due to hit pharmacy shelves.
Novogen to begin trials with phenoxodiol-derivative
12 May, 2004 by Melissa TrudingerNovogen (ASX: NRT) has been approved to commence a Phase I clinical trial at Sydney's St George Hospital of its second anti-cancer drug NV-18, a derivative of the company's first generation drug phenoxodiol.
Abbott resolution translates to profit for Peptech
11 May, 2004 by Graeme O'NeillSydney-based biotech Peptech (ASX:PTD) is enjoying halcyon days, today revealing an after-tax profit of AUD$29.5 million for the half-year to March 31, on total revenues of $45.5 million.
Biota sues GSK for lost Relenza revenues
05 May, 2004 by Renate Krelle and Melissa TrudingerVictorian drug-developer Biota released a bombshell this morning, announcing that it was suing its marketing partner, UK-based GlaxoSmithKline (GSK), for failure to promote and support its influenza drug, Relenza in the 5 years since the drug was launched.
Norwood Immunology set for May IPO in London
05 May, 2004 by ReutersAustralian biotech company Norwood Immunology plans to list its shares in London in late May, which should value the company at about £115 million (AUD$283 million).
Avastra plans $8 million IPO for BioWeld
05 May, 2004 by Renate KrelleSydney-based biotechnology company Avastra has announced it will open its $8 million share offer this Friday. Avastra will offer eight million shares at $1 per share, equivalent to 29 per cent of the company. Managing Director Paul Ralph said that with oversubscriptions this may rise to 33 per cent.
Progen anti-cancer compound earns orphan drug status
04 May, 2004 by Iain ScottBrisbane-based Progen (ASX:PGL) has earned 'orphan drug' status from the US Food and Drug Administration for its much-touted PI-88 compound, for treatment of malignant melanoma.
